Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.
26 April 2024
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company's mass spectrometry services for the analysis of samples for an on-going clinical trial. This project will be provided utilising the Good Clinical Laboratory Practice ("GCLP") accreditation obtained by Proteome Sciences specifically for this type of project. The contract value is in excess of £500,000 and the Company considers that a good proportion of the work should be completed in this financial year.
Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:
"We have experienced good customer interest in our services in the first Quarter reflected by the considerable increase in customer contact and quotations across a broad range of projects. In this contract the client selected our targeted assay workflows with GCLP compliance as a quality standard specifically to monitor the performance of their investigational drug in their clinical trial. We expect the increased levels of interest in our services activities to continue through 2024 and look forward to further clinical trial projects."
- Ends -
For further information:
| ||||||||||||||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
